tbuckley/cabot-search huggingface dataset:
THU0190 A Six-Week Progressive Resistance Training Class Improves Function and Fatigue in RA Patients:
Authors: B. Berntzen, L. Erwood, T. Bellerby, E. Price, D. Collins, L. Williamson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is associated with adverse changes in body composition and physical function that persist despite pharmaceutical treatment. Randomised control trial evidence has shown that Progressive Resistance Training (PRT) is safe and efficacious in restoring lean mass and function in patients with RA. We set up our own PRT programme for RA patients to explore whether similar results could be achieved in an NHS setting. <h3>Methods</h3> RA patients were invited to attend a PRT programme of six, weekly class held under the supervision of a Senior Physiotherapist. Newly diagnosed and established RA were included. The exercises used within the circuit are: wall slides, chest press, leg extension, rowing, balance board work, triceps extensions, bicep curls, clam, bridging, standing calf raises and step ups. Classes included up to 10 patients at a time. Data collected at induction and after six weeks included demographics, BMI, percentage body fat, grip strength, 60 second Sit to Stand test, HAQ and FACIT (fatigue) scores. After the six-week PRT programme patients were encouraged to continue at home or referred to their local gym. <h3>Results</h3> Of 34 RA Patients invited, 27 started and 21 completed the 6 week PRT course. Mean age 54 (range 17–78) years; 71% F; 50% RF positive. 11 (32%) patients were diagnosed within 3 months of starting the class. There was no difference in results between recently diagnosed and established RA patients. After six weeks there was a significant improvement in: HAQ mean (range) 1 (0–2.9) vs 0.8 (0–2.5) p=0.03; Body Fat Composition mean (range) 38.0% (21.5%&gt;51%) vs 36.9% (26.3%&gt;48.2%) p=0.02; Sit to Stand mean (range) 20.0 (8–36) vs 23 (9–42) p=0.02. There was a trend towards improvement mean (range) in: handgrip strength 22.0 (2–54) vs 25.8 (5–54) p=0.21 and FACITF score 29.5 (18–49) vs 35.6 (19–49) p=0.05. <h3>Conclusions</h3> We present an effective model for PRT workable in the NHS, which encourages patient to take control of their own exercise regimes. The class setting fosters motivation, confidence and a belief in exercise as part of effective treatment. This brief intervention was associated with significant improvement in various aspects of physical function, Grip strength, HAQ and Fatigue scores. <h3>Disclosure of Interest</h3> None declared
Mutational Spectrum Analysis of Interesting Correlation and Interrelationship Between RNA Splicing Pathway and Commonly Targeted Genes in Myelodysplastic Syndrome
Authors: Yasunobu Nagata, Masashi Sanada, Ayana Kon, Kenichi Yoshida, Yuichi Shiraishi, Aiko Sato-Otsubo, Hiraku Mori, Ken Ishiyama, Mamiko Sakata-Yanagimoto, Naoshi Obara, Masao Nagasaki, Shuichi Miyawaki, Shigeru Chiba, Satoru Miyano, Shih Lee Yung, H. Phillip Koeffler, Seishi Ogawa
Journal: Blood (2011)
Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).
Authors: David Jacobsohn, Xiaoyu Chai, Brenda Kurland, Sally Arai, Mukta Arora, Corey Cutler, Madan Jagasia, Steven Z. Pavletic, Georgia Vogelsang, Stephanie J. Lee, Mary E.D. Flowers
Journal: Blood (2009)
AB0412 Exploratory Results from The Bliss and Illuminate Trials Support The Design of The CHABLIS-SC1 Trial, A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study To Evaluate The Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus: Table 1.
Authors: J.T. Merrill, V. Strand, C. Hislop, M. Gangal, R.S. Martin, K.C. Kalunian
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Targeted, biologic inhibitors of B-cell Activating Factor (BAFF) have been evaluated in 4 large Phase 3 clinical trials in nearly 4000 patients with Systemic Lupus Erythematosus (SLE). Data from these studies identify that greatest treatment effect is discernable using more stringent endpoints in patients who enter with higher disease activity scores, taking more corticosteroids, and/or have anti-double-stranded DNA (dsDNA) and low complement C3 or C4<sup>1,2,3</sup>. <h3>Objectives</h3> The CHABLIS-SC1 study (NCT01395745) has completed enrollment and will be the first trial to prospectively evaluate the impact of treatment on the above "responder populations" using the BAFF inhibitor, blisibimod. <h3>Methods</h3> CHABLIS-SC1 enrolled subjects positive for anti-nuclear and/or anti-dsDNA antibodies with SELENA-SLEDAI≥10 despite corticosteroid therapy. Subjects were randomized to have blisibimod or placebo added to their background medications. Efficacy will be evaluated using the SLE Responder Index-6 (SRI-6) at Week 52, defined as: ≥6 point reduction in SELENA-SLEDAI; no new BILAG A or 2 new BILAG B organ domain scores; and no worsening in Physician9s Global Assessment. <h3>Results</h3> Table 1 identifies that the baseline characteristics of the 442 subjects enrolled into the CHABLIS-SC1 study more frequently meet all descriptions of "responder populations" identified previously<sup>2–7</sup>. In previous studies, the SRI-6 was associated with lower placebo responder rates and greater benefit of BAFF inhibitors over placebo. <h3>Conclusions</h3> BAFF inhibitors are known to be at least modestly effective in SLE and impact B Cell-driven immunopathology such as autoantibodies. The CHABLIS-SC1 study design will determine whether enrichment for the hypothesized "responder population," patients with more severe, immunologically active SLE, will robustly discriminate treatment impact of blisibimod when background therapy is maintained. <h3>References</h3> van Vollenhoven RF et al. Ann Rheum Dis. 2012;71:1343. Isenberg DA, et al. Ann Rheum Dis. 2015 Sep. Merrill JT et al. Ann Rheum Dis. 2015 Aug. Dooley MA et al Lupus, 2013;22(1):63, Manzi et al Ann Rheum Dis. 2012;71(11):1833, Merrill et al 2015 (EULAR abstract); Benlysta FDA Drug Approval Package. <h3>Acknowledgement</h3> We wish to thank all of the patients, Investigators and study personnel participating in this trial. <h3>Disclosure of Interest</h3> J. Merrill Consultant for: Anthera Pharmaceuticals Inc, V. Strand Consultant for: Anthera, C. Hislop Shareholder of: Anthera, Employee of: Anthera, M. Gangal Shareholder of: Anthera, Employee of: Anthera, R. Martin Shareholder of: Anthera, Employee of: Anthera, K. Kalunian Consultant for: Anthera
PTU-111 Teduglutide Reduces the Need for Parenteral Support in Patients with Short Bowel Syndrome Who Have Ultra-Short Remnant Bowel and/or No Colon-in-Continuity
Authors: SM Gabe, K Fujioka, S Schneider, NN Youssef, U-F Pape, K Jeejeebhoy
Journal: Gut (2016)

<h3>Introduction</h3> Prior to the availability of teduglutide (TED), functional bowel length was recognised as an important prognostic factor in patients (pts) with short bowel syndrome (SBS).<sup>1</sup> Pts with shorter residual small bowel following intestinal resection generally are more likely to remain chronically dependent on parenteral support (PS) to meet fluid and nutrient needs.<sup>1</sup>TED enhanced absorption and reduced the PS volume needed to maintain clinical status in a wide range of pts with varying etiologies and durations of SBS.<sup>2-4</sup> In the STEPS (NCT00798967) study, 27/43 (63%) TED-treated vs 13/43 (30%) placebo-treated pts achieved responder criteria (≥20% reduction in weekly PS volume from baseline at Wks 20 and 24).<sup>4</sup> Mean PS volume reduced by 4.4 L/wk at Wk 24 from the baseline mean volume of 12.9 L/wk. This subanalysis was undertaken to determine the impact of TED in pts with ultra-short (≤40 cm) remnant bowel and/or no colon-in-continuity. <h3>Methods</h3> Data from pts randomised to TED 0.05 mg/kg/day in STEPS whose bowel length was known (n = 40) were assessed by descriptive statistics. Also, data from all pts randomised to TED 0.05 mg/kg/day in STEPS, regardless of bowel length (n = 43), were analysed according to presence or absence of colon-in-continuity. No between-group comparisons were done owing to the small sample size. <h3>Results</h3> Responder criteria were met by similar percentages of pts regardless of bowel length, including pts with remnant bowel length ≤25 or ≤40 cm <b>(Table)</b>. At Wk 24, pts in each of these 2 groups with ultra-short bowel had mean decreases in weekly PS volume of 3.9 and 3.6 L, respectively. Data analysis from all pts randomised to TED, regardless of bowel length, found that 13/17 (77%) pts without colon-in-continuity and 14/26 (54%) pts with colon-in-continuity met the responder criteria. Furthermore, the mean change in weekly PS volume at Wk 24 was greater for pts with no colon-in-continuity (–6.4 L/wk) than pts with colon-in-continuity (–3.2 L/wk). <h3>Conclusion</h3> Pts without colon-in-continuity show a numerically greater response to TED, perhaps reflecting natural adaptation by GLP-2 secreting cells in pts with colon-in-continuity. The overall findings reinforce the benefits of treatment with TED 0.05 mg/kg/day to enhance absorptive capacity in SBS regardless of remnant anatomy. <h3>References</h3> 1 O’Keefe, <i>et al</i>. <i>Clin Gastroenterol Hepatol</i> 2006;<b>4</b>:6–10. 2 Jeppesen, <i>et al</i>. <i>Gut</i> 2005;<b>54</b>:1224–31. 3 Jeppesen, <i>et al</i>. <i>Gut</i> 2011;<b>60</b>:902–14. 4 Jeppesen, <i>et al</i>. <i>Gastroenterology</i> 2012;<b>143</b>:1473–81. <h3>Disclosure of Interest</h3> None Declared
THU0099 Cardiovascular MR (CMR) Evidence for Reduced LV Mass in Rheumatoid Arthritis (RA), Suggesting Pathology Other than Atherosclerosis for Heart Failure: Table 1.
Authors: L.-A. Bissell, B. Erhayiem, E.M. Hensor, G. Fent, A. Burska, H. Donica, S. Plein, M.H. Buch, J.P. Greenwood, J. Andrews
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> An increased risk of heart failure in RA exists<sup>1</sup>. Aetiology is unclear with some evidence that cardiomyopathy may occur early in RA, from pathology distinct to atherosclerosis<sup>3</sup>. Large well characterised CMR-RA studies to investigate pathogenesis are few<sup>2</sup>. <h3>Objectives</h3> To evaluate sub-clinical CVD in an asymptomatic-CVD established RA cohort compared to healthy controls (HC), using reference standard CMR-measured outcomes &amp; novel CMR-measures of carotid artery. <h3>Methods</h3> 76 ACR1987 RA patients (pts) with dis.&gt;5yrs, no CVD/diabetes, assessed for CV traditional risk factor (TRFs)/RA profile, pulse wave velocity (PWV), non-contrast 3T CMR (heart &amp; carotids) reported by CMR-cardiologists, compared to 26 HC. Carotid measures inc. mean (MWT) &amp; maximum (MxWT) wall thickness, wall (WVol) &amp; luminal (LVol) volume &amp; WVol-index (WVol-I, WVol/(WVol+LVol)). UVA variables (var.)=TRFs, BMI, waist/hip ratio (WHR), HOMA-IR, NTproBNP, dis. duration (ddur), 3vDAS28, ACPA, HAQ-DI, joint surgery hx, biologic use &amp; PWV. MVA var.=age/sex/known associated (ass.) var./UVA r&gt;0.3. <h3>Results</h3> Mean (SD) age (yrs) of RA pts; 60 (9.2), 74% female; HC 52 (11.4), 54% female. Median (IQR) ddur 16.5 (10.7, 25.7)yrs, 81% ACPA+ve, DAS28CRP 2.59 (1.30, 3.33), 67% on biologic. There were no significant differences in lipids/glucose/HOMA-IR between RA/HC. Trend for higher NT-proBNP in RA seen. In MVA (inc. age/sex), increasing ddur ass. with NTproBNP (0.5% rise in NTproBNP per 1% increase in ddur, p0.034). RA pts (after adj. for age/sex/TRFs) had reduced LVmass/BSA, LVEF, native T1 values &amp; increased strain (Mid-S9) vs HC; no difference seen for LVEDV, LVESV, SV, LVmass/EDV, torsion or arterial stiffness (PWV/distensibility). No significant differences in carotid measures between RA/HC seen. In RA pts, 10yr JBS2 CV risk score correlated with WVol (r0.377 p=0.004) &amp; LVol (r0.441 p=0.001). TRFs ass. with cardiac &amp; carotid measures in RA. <h3>Conclusions</h3> CMR evidence for reduced LV mass in RA, suggesting pathology other than atherosclerosis as the cause of heart failure; perhaps microvascular dysfunction. TRFs, not RA features, are important determinants of CMR measures of subclinical CVD in RA. <h3>References</h3> ArthRheum 2005;52:412–20 EULAR 2015 OP0163 A&amp;R 2010:62v4 <h3>Disclosure of Interest</h3> None declared
Distinct Transforming and Leukemogenic Activities of Tel-Arg and Tel-Abl Oncogenes in Mice: Possible Negative Role for the Transforming Activity in C-Terminus of Arg
Authors: Keiko Okuda, Nari Harakawa, Richard A VanEtten, Nihal Patel, Naochika Domae, Yuko Sato, Hideyo Hirai
Journal: Blood (2008)
Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody
Authors: Paul Noordhuis, Monique Terwijn, Arjo P Rutten, Linda Smit, Gert J. Ossenkoppele, Gerrit J. Schuurhuis
Journal: Blood (2010)
AB0874 Juvenile Idiopathic Arthritis. Follow-Up in Adulthood: A Descriptive Study: Table 1
Authors: L. Expόsito Pérez, J.J. Bethencourt Baute, F. Άlvarez Reyes, M. García González, H. Sánchez Pérez, S. Bustabad Reyes
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Juvenile Idiopathic Arthritis (JIA) is the most prevalent clinical entity between childhood rheumatic diseases. Treatment and follow-up in adulthood of patients diagnosed with JIA is not well defined, it is therefore important to define the clinical features and complications during adulthood of these patients, and thus achieve better management of the disease. <h3>Objectives</h3> To describe the clinical features and complications in adult patients diagnosed with JIA. <h3>Methods</h3> Cross-sectional descriptive study where the evolution of 44 patients older than 18 years diagnosed with JIA in current monitoring Services Rheumatology two tertiary hospitals is determined. <h3>Results</h3> The current average age of the patients is 31.06 years (18–64); sex: 34 woman,10 men; average age of diagnosis was 9.9 years (1–16); mean duration of disease 21.2 years (4–53). The patient characteritics and their complications are specified in Table 1. During follow-up the number of relevant infections occurred in 9 patients (20.5%): 4 polyarticular JIA (community-acquired pneumonia, pyelonephritis E. coli, catheter-related sepsis and repeat UTI), 2 in JIA Oligoarticular 2 with systemic JIA and another in psoriatic way; and they have required hospitalization at some point in the evolution of his illness 80% of systemic JIA, 71.4% of polyarticular JIA and 66.6% of oligoarticular JIA. Orthopedic surgery was performed in 14 patients (32%); JIA subtypes with higher number of surgeries were systemic and polyarticular RF positive. The most common surgeries: total knee and hip prosthesis. All patients have been treated with FAME (especially LFN and MTX), except for one patient with psoriatic JIA and 2 ERA B27+. Biological treatment has been used in 23 patients (52.3%): polyarticular JIA (47.6%), systemic onset JIA (100%), oligoarticular JIA (50%), arthritis-entesistis (50%). 25% received a biological; 16% received two biological and 10% three or more biological. <h3>Conclusions</h3> Despite the small number of patients in our series, we have determined the following:1)The most frequent form of JIA on follow-up in adulthood is polyarticular (47.7%). 2)93.2% of patients received FAME treatment. 3) More than half of patients (52.3%) received treatment with biologics. 4) Relevant infections occurred in 20.5% of patients, especially in subtype polyarticular JIA. 5)The vast majority of orthopedic surgeries were performed in the pre-biological age. JIA subtypes that needed more systemic way were systemic JIA and polyarticular RF positive, the most common surgeries total hip and knee prosthesis. <h3>References</h3> Cohorte de adultos jόvenes diagnosticados con enfermedad reumática crόnica infantil. Lόpez Robledillo, J.C. Sociedad Española de Reumatología. <h3>Disclosure of Interest</h3> None declared
Beyond the Barriers of Light Penetration: Strategies, Perspectives and Possibilities for Photodynamic Therapy
Authors: Srivalleesha Mallidi, Sriram Anbil, Anne-Laure Bulin, Girgis Obaid, Megumi Ichikawa, Tayyaba Hasan
Journal: Theranostics (2016)

Photodynamic therapy (PDT) is a photochemistry based treatment modality that involves the generation of cytotoxic species through the interactions of a photosensitizer molecule with light irradiation of an appropriate wavelength.PDT is an approved therapeutic modality for several cancers globally and in several cases has proved to be effective where traditional treatments have failed.The key parameters that determine PDT efficacy are 1. the photosensitizer (nature of the molecules, selectivity, and macroscopic and microscopic localization etc.), 2. light application (wavelength, fluence, fluence rate, irradiation regimes etc.) and 3. the microenvironment (vascularity, hypoxic regions, stromal tissue density, molecular heterogeneity etc.).Over the years, several groups aimed to monitor and manipulate the components of these critical parameters to improve the effectiveness of PDT treatments.However, PDT is still misconstrued to be a surface treatment primarily due to the limited depths of light penetration.In this review, we present the recent advances, strategies and perspectives in PDT approaches, particularly in cancer treatment, that focus on increasing the 'damage zone' beyond the reach of light in the body.This is enabled by a spectrum of approaches that range from innovative photosensitizer excitation strategies, increased specificity of phototoxicity, and biomodulatory approaches that amplify the biotherapeutic effects induced by photodynamic action.Along with the increasing depth of understanding of the underlying physical, chemical and physiological mechanisms, it is anticipated that with the convergence of these strategies, the clinical utility of PDT will be expanded to a powerful modality in the armamentarium for the management of cancer.
Urinary Hepcidin Excretion in Patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).
Authors: Asher Winder, Rafi Lefkowitz, Hussam Ghoti, Merav Leiba, Tomas Ganz, Elizabeta Nemeth, E.A. Rachmilewitz
Journal: Blood (2006)
Comparative Clinical and Gene Expression Analysis of Sickle Cell Anemia and Hemoglobin SC Disease
Authors: Kathleen Vaughan, Lena Diaw, Wang Zhengyuan, Chia-Hao Liu, Marci Barr, Deepika Darbari, Kimberley A. Woodhouse, Darlene Allen, Meghan Quinn, Catherine Seamon, Elizabeth S. Klings, Nalini Raghavachari, James G. Taylor VI
Journal: Blood (2014)
Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin’s Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.
Authors: María-Dolores Caballero, Rodrigo Martino, María-Victoria Mateos, Javier Briones, Javier de la Serna, Jose-Francisco Tomás, Reyes Arranz, Jose-Luis Díez, Vicente Rubio, Josep-María Ribera, José-María Moraleda, Guillermo Sanz, Alvaro Urbano, José Sarrá, Antonia Sampol, Jordi Sierra, J. F. San Miguel
Journal: Blood (2006)
CD56+ AML Is Strongly Associated with AML1/ETO Rearrangement and CNS Involvement in Childhood AML.
Authors: Hye Ryun Lee, Dong Soon Lee, Inho Kim, Sung-Soo Yoon, Seonyang Park, Byoung Kook Kim, Hyoung Jin Kang, Hee Young Shin, Hyo Seop Ahn, Hyun Kyung Kim, Myoung Hee Park, Han Ik Cho
Journal: Blood (2007)
FRI0197 Time Lag of Improvement in Synovial Hypertrophy Compared To Rapid Response in Power Doppler Synovial Vascularity in Post-Adalimumab Rheumatoid Arthritis
Authors: Y.-C. Chen, J.-F. Chen, T.-T. Cheng
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> In previous studies, the patients achieved greater disease control by adalimumab at 24 weeks, this response was maintained over the next 24 weeks<sup>1</sup>, however, we could not found the characteristic in image to confirm the clinical presentations. <h3>Objectives</h3> This study aimed to validate the use of power Doppler ultrasonography (PDUS) for evaluating synovial vascularity and synovial hypertrophy for synovitis in patients with rheumatoid arthritis (RA) treated with adalimumab. <h3>Methods</h3> The synovial disease activity and vascularity of RA on both wrists (radio-carpal joint) were assessed using GS and PDUS to derive the composite US scores based on abnormal counts and severity. The relationship between each measure was determined. <h3>Results</h3> The 71 patients who received adalimumab therapy had significantly decreased DAS28, ESR, and CRP. After one month, PD score decreased and then remained low for 12 months. Synovial hypertrophy did not change until 3–6 months after, when it started to improve (<i>p</i>=0.017). By multivariate analysis, sex, age, BMI, and DAS28 did not lead to any difference between synovial hypertrophy and PDUS changes (<i>p</i>=0.498). <h3>Conclusions</h3> Composite US markers of synovial hypertrophy correlate significantly to the DAS28 score and ESR/CRP in adult RA. The time needed for synovial hypertrophy to decrease may be up to 3–6 months after adalimumab therapy. Using ultrasound Doppler measurements predict success of treatment with anti-TNF-alpha has been a trend in monitoring biological therapy in patients with RA <h3>References</h3> Keystone EC, et al. Arthritis and rheumatism. May 2004;50(5):1400–1411. <h3>Disclosure of Interest</h3> None declared
A Hyperactive Transcriptional State Marks Genome Reactivation during Mitotic Exit
Authors: Gerd A. Blobel, Chris C.S. Hsiung, Peng Huang, Cheryl Keller, Paul Ginart, Kristen Jahn, Caroline Bartman, Aaron James Stonestrom, Perry Evans, Belinda Giardine, Ross C. Hardison, Arjun Raj
Journal: Blood (2015)
A Single Center Analysis over a Ten Year Period on Transplant Related Mortality (TRM), Early Relapse (ER) and Failure of Blood Cell Reconstitution (FBR) in High-Risk (HR) Cancer Patients (PTS) Undergoing Autologous PBSCT (auto-PBSCT): Frequency, Outcome and Prognostics.
Authors: Monika Engelhardt, Carsten Doeing, Gabriele Ihorst, Dagmar Wider, Juergen Finke
Journal: Blood (2004)
Changes in Plasma TGF-β1 Levels in a Murine Model of Aortic Stenosis (Surgical Constriction of the Ascending Aorta) in C57Bl/6 (wild-type) Mice and Mice with a Targeted Deletion of Platelet TGF-β1
Authors: Wei Wang, Alexander Meyer, Barry S. Coller, Jasimuddin Ahamed
Journal: Blood (2012)
Imatinib Combined with Intensive HAM Chemotherapy as Consolidation of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph1-ALL). Preliminary Results of the AFR03 Phase I/II Study.
Authors: Herve Dombret, Francis Witz, Stephane De Botton, Jean-Michel Cayuela, Eric Delabesse, Claude Preudhomme, Francoise Huguet-Rigal, Anne Vekhoff, Charles Dauriac, Sandrine Hayette, Norbert Vey, Xavier Thomas, Tibor Kovacsovics, Andre Delannoy, Amel Ouslimani, Elodie Soler, Jean Gabert, Elizabeth Macintyre, Jean-Paul Vernant
Journal: Blood (2004)
Rituximab-Supplemented High-Dose Sequential Chemotherapy (HDS) Has Superior Response Rate and Event-Free Survival (EFS) Compared to R-CHOP in Poor Risk Follicular Lymphoma (FL) at Diagnosis: Results from a Multicenter Randomized GITMO Trial.
Authors: Marco Ladetto, Irene Ricca, Fabio Benedetti, Umberto Vitolo, Caterina Patti, Alessandro Rambaldi, Anna Marina Liberati, Maurizio Musso, Alessandro Pulsoni, Attilio Olivieri, Enzo Pavone, Enrico Pogliani, Delia Rota Scalabrini, Andrea Gallamini, Vincenzo Callea, Barbara Mantoan, Mario Boccadoro, Ignazio Majolino, Paolo Corradini, Alessandro M. Gianni, Corrado Tarella
Journal: Blood (2005)
Whole-Exome Sequencing Identifies Germline IDH2 and IDH3 mutations That Predispose to Myeloid Neoplasms
Authors: Remco Molenaar, Srinivasa Reddy Sanikommu, Bhumika J. Patel, Bartlomiej Przychodzen, Cornelis J van Noorden, Tomas Radivoyevitch, Hideki Makishima, Hetty E. Carraway, Jaroslaw P. Maciejewski
Journal: Blood (2015)
Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).
Authors: Xiaomeng Huang, Sebastian Schwind, Ann-Kathrin Eisfeld, Bo Yu, Ramasamy Santhanam, Pia Hoellerbauer, Yan Jin, Christopher Hickey, Jiuxia Pang, Kenneth K. Chan, Danilo Perrotti, Natarajan Muthusamy, John C. Byrd, William Blum, Clara D. Bloomfield, Shujun Liu, Ramiro Garzon, Robert J. Lee, L. James Lee, Guido Marcucci
Journal: Blood (2012)